FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282967424> ?p ?o ?g. }

• W4282967424 endingPage "6696" @default.
• W4282967424 startingPage "6696" @default.
• W4282967424 abstract "(1) Background: With new potential drug targets emerging, combination therapies appear attractive to treat non-alcoholic steatohepatitis (NASH) and fibrosis. Chemokine receptor CCR2/5 antagonists can improve fibrosis by reducing monocyte infiltration and altering hepatic macrophage subsets. Fibroblast growth factor 21 (FGF21) may improve NASH by modulating lipid and glucose metabolism. We compared effects of single drug to combination treatment as therapeutic strategies against NASH. (2) Methods: We analyzed serum samples and liver biopsies from 85 nonalcoholic fatty liver disease (NAFLD) patients. A CCR2/5 inhibitor (BMS-687681-02-020) and a pegylated FGF21 agonist (BMS-986171) were tested in male C57BL/6J mice subjected to dietary models of NASH and fibrosis (choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) up to 12 weeks; short- (2w) or long-term (6w) treatment). (3) Results: In NAFLD patients, chemokine CCL2 and FGF21 serum levels correlated with inflammatory serum markers, only CCL2 was significantly associated with advanced liver fibrosis. In rodent NASH, CCR2/5 inhibition significantly reduced circulating Ly6C+ monocytes and hepatic monocyte-derived macrophages, alongside reduced hepatic inflammation and fibrosis. FGF21 agonism decreased body weight, liver triglycerides and histological NASH activity. Combination treatment reflected aspects of both compounds upon short- and long-term application, thereby amplifying beneficial effects on all aspects of steatohepatitis and fibrosis. (4) Conclusions: CCR2/5 inhibition blocks hepatic infiltration of inflammatory monocytes, FGF21 agonism improves obesity-related metabolic disorders. Combined therapy ameliorates steatohepatitis and fibrosis more potently than single drug treatment in rodent NASH, corroborating the therapeutic potential of combining these two approaches in NASH patients." @default.
• W4282967424 created "2022-06-17" @default.
• W4282967424 creator A5003706299 @default.
• W4282967424 creator A5004287022 @default.
• W4282967424 creator A5004357718 @default.
• W4282967424 creator A5006812658 @default.
• W4282967424 creator A5006858899 @default.
• W4282967424 creator A5007388418 @default.
• W4282967424 creator A5018154234 @default.
• W4282967424 creator A5027922038 @default.
• W4282967424 creator A5034044249 @default.
• W4282967424 creator A5034833350 @default.
• W4282967424 creator A5043754532 @default.
• W4282967424 creator A5044828759 @default.
• W4282967424 creator A5053851243 @default.
• W4282967424 creator A5069578680 @default.
• W4282967424 creator A5083107126 @default.
• W4282967424 creator A5083825910 @default.
• W4282967424 date "2022-06-15" @default.
• W4282967424 modified "2023-10-18" @default.
• W4282967424 title "Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis" @default.
• W4282967424 cites W1967972402 @default.
• W4282967424 cites W2000665430 @default.
• W4282967424 cites W2001837599 @default.
• W4282967424 cites W2016617561 @default.
• W4282967424 cites W2022273281 @default.
• W4282967424 cites W2022790785 @default.
• W4282967424 cites W2034212495 @default.
• W4282967424 cites W2063437798 @default.
• W4282967424 cites W2067740038 @default.
• W4282967424 cites W2114650931 @default.
• W4282967424 cites W2133706171 @default.
• W4282967424 cites W2139654088 @default.
• W4282967424 cites W2221554994 @default.
• W4282967424 cites W2256248004 @default.
• W4282967424 cites W2338564836 @default.
• W4282967424 cites W2363023549 @default.
• W4282967424 cites W2467384826 @default.
• W4282967424 cites W2492767679 @default.
• W4282967424 cites W2580009538 @default.
• W4282967424 cites W2611477496 @default.
• W4282967424 cites W2746863374 @default.
• W4282967424 cites W2755905165 @default.
• W4282967424 cites W2760098333 @default.
• W4282967424 cites W2802008491 @default.
• W4282967424 cites W2806839461 @default.
• W4282967424 cites W2810423511 @default.
• W4282967424 cites W2889932786 @default.
• W4282967424 cites W2892849077 @default.
• W4282967424 cites W2905440332 @default.
• W4282967424 cites W2924281947 @default.
• W4282967424 cites W2934946727 @default.
• W4282967424 cites W2944563907 @default.
• W4282967424 cites W2958296451 @default.
• W4282967424 cites W2982370215 @default.
• W4282967424 cites W2993083975 @default.
• W4282967424 cites W2994320390 @default.
• W4282967424 cites W2997154811 @default.
• W4282967424 cites W2998756962 @default.
• W4282967424 cites W2999131584 @default.
• W4282967424 cites W3000140653 @default.
• W4282967424 cites W3092264591 @default.
• W4282967424 cites W3109035992 @default.
• W4282967424 cites W3135465578 @default.
• W4282967424 cites W3143409077 @default.
• W4282967424 cites W3160163020 @default.
• W4282967424 cites W3206948891 @default.
• W4282967424 cites W4214523533 @default.
• W4282967424 cites W4221113434 @default.
• W4282967424 cites W4254965081 @default.
• W4282967424 doi "https://doi.org/10.3390/ijms23126696" @default.
• W4282967424 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35743140" @default.
• W4282967424 hasPublicationYear "2022" @default.
• W4282967424 type Work @default.
• W4282967424 citedByCount "20" @default.
• W4282967424 countsByYear W42829674242022 @default.
• W4282967424 countsByYear W42829674242023 @default.
• W4282967424 crossrefType "journal-article" @default.
• W4282967424 hasAuthorship W4282967424A5003706299 @default.
• W4282967424 hasAuthorship W4282967424A5004287022 @default.
• W4282967424 hasAuthorship W4282967424A5004357718 @default.
• W4282967424 hasAuthorship W4282967424A5006812658 @default.
• W4282967424 hasAuthorship W4282967424A5006858899 @default.
• W4282967424 hasAuthorship W4282967424A5007388418 @default.
• W4282967424 hasAuthorship W4282967424A5018154234 @default.
• W4282967424 hasAuthorship W4282967424A5027922038 @default.
• W4282967424 hasAuthorship W4282967424A5034044249 @default.
• W4282967424 hasAuthorship W4282967424A5034833350 @default.
• W4282967424 hasAuthorship W4282967424A5043754532 @default.
• W4282967424 hasAuthorship W4282967424A5044828759 @default.
• W4282967424 hasAuthorship W4282967424A5053851243 @default.
• W4282967424 hasAuthorship W4282967424A5069578680 @default.
• W4282967424 hasAuthorship W4282967424A5083107126 @default.
• W4282967424 hasAuthorship W4282967424A5083825910 @default.
• W4282967424 hasBestOaLocation W42829674241 @default.
• W4282967424 hasConcept C106646824 @default.
• W4282967424 hasConcept C126322002 @default.
• W4282967424 hasConcept C12823836 @default.

• next